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New Hope Now for Bowed Tendons
by Virginia B. Reef, D. VM.

U

ltrasonography is a well-established,
valuable tool for diagnosing the
type and severity of tendon and ligament
injuries in horses.
Its use as part of a rehabilitation pro
gram can help the veterinarian, trainer
and owner success fully return the horse
to competition, minimizing the chances
of the horse's returning successfully to
its previous level of competition.
Beta-aminoproprionitrile (BAPN ) is a
scar-remodeled drug which has been
shown to improve the quality of tendon
and ligament repair in horses.
BAPN is found in seeds of the wild
sweet pea, Lathyru s odoratus. BAPN , ad
ministered in the early stages of sca r for
mation , blocks the enzyme Iysyl oxidase
and thu s blocks the formation of col
lagen cross-links in the area of injury.
This brief interruption of collagen cross
linking allows for physiologically benefi
cial scar remodeling to occur.
Clinical trials using beta
aminoproprionitrile fumarate (BAPN-F)
in horses with acute bowed tendons have
demonstrated improved tendon healing.
Carefully designed double-blind placebo
controlled trials showed the effic ac y of
thi s treatment. These studies are an im
pOltant new application of ultrasonogra
phy and should help veterinary medicine
make significant advances in the treat
ment of tendon and ligament inj uries in
horses.
DOUble-blind placebo controlled trials
have not previously been performed to
eval uate the efficacy of other treatments
fo r tendon and ligament injuries.
More than 200 horses with a recent
injury (one to three months) to the s uper
ficial digital flexor tendon have been
treated with intralesional BAPN-F
(Alcoa Inc., Tucson, AZ) following the
tendon injury, primalily at the University
of Pennsylvania School of Veterinary
Medicine at New Bolton Center in
Kennett Square, PA by my coworkers
and me, and at Randall Veterinary Hospi
tal in Warrensville Heights, OH, by Dr.
Ron Genovese and his coworkers. This
drug has al so been administered to
horses with other tendon and liga ment
InJuries.

All horses were racing,
training or involved in other
types of equestrian competi
tion at the time the injury oc
curred. The majority of treated
horses were racehorses.
The treated horses had large areas of
damage to the superficial digital flexor
tendon. Affected tendons were at least
50% larger than normal or the cross
sectional area of the affected tendon was
at least 1.5cm. The lesion involved at
least 25 % of the tendon's cross-sectional
area at its worst and extended over at
least three of seven zones.
Following a sterile prep, BAPN-F was
injected throughout the injured area with
a 27 - gauge needle every other day for a
total of five treatments.
Horses were then placed in a rigorou s
low-level controlled exercise program
with frequent ultrasound monitoring. The
treated horses began walking 30 minutes
per day for four weeks, which then in
creased to 45 minutes daily for another
four week s. All subsequent increases in
the horse's exercise were based upon im
provement in the ultrasound
(sonographic) findings.
If sonographic improvement was de
tected eight weeks following treatment, a
small amount of jogging (no more than
five minutes per day at a five to six
minute per mile pace) or swimming exer
ci se was added to the exercise program.
This was increased to 10 minutes per day
if sonographic improvement was de
tected at 12 weeks.
If continued sonographic improve
ment occurred at 16 weeks, then turnout
in a small paddock was permitted. The
amount of jogging exercise remained
stable or continued to increase by five
minutes per month until 24 weeks.
If continued sonographic improve
ment occurred at 24 weeks, the horses
started galloping. The first start occurred
no sooner than 40 weeks following treat
ment and was longer in horses with more
severe injuries.
Follow-up ultrasound examinations
revealed a better quality of tendon repair
in the BAPN-F treated horses, when
compared to place bo controls.

Tendon cross-sectional area was sig
nificantly decreased , and fiber alignment
was improved significantly at 16 weeks
in horses treated with the seven or eight
mg doses of BAPN-F. These findings
persi sted as the horse went on into more
rigorous training.
Any increase in tendon cross-sec
tional area (thickening) between exami
nations resulted in the horse remaining at
the sa me exercise level for an additional
four weeks, unless the increase in tendon
cross-sectional area was greater than or
equal to 25 %, in which case the amount
of trotting exercise was decreased or dis
continued altogether for the subsequent
four weeks.
Increases in tendon cross-sectional
area of thi s magnitude indicated exces
si ve tendon loading for the stage tendon
healing and increased the ri sk for re
llljury.
A gradually increasing controlled ex
ercise program should be a routine part
of the rehabilitation of horses with ten
don and ligament injuries.
Periodic ultrasound examinations
should be performed prior to each in 
crease in the horse 's exercise level to be
sure that the horse is ready to advance to
the next exercise level.
Long-term follow-up data is still be
ing obtained on these horses to evaluate
their return to performance. But initial
studies indicate a sig nificantly high per
centage of BAPN- F tre ated horses are
able to return successfully to competition
without recurrence of the injury, the ulti
mate goal of the treatment of equine ath
letes with tendon injuries . •
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